Our Mission
We are dedicated to establishing a drug discovery and early-stage development company that is based on innovation, scientific rigor and integrity. Our goal is to create novel products to meet critical patient needs, including: Novel imaging-based diagnostic tools to improve the detection of occurrence, progression, and regression of neurological diseases; and Novel therapies to improve the treatment of human neurological conditions.
Our Vision and Values
For Patients
For Sciences
For Our Partners
APRINOIA believes living quality and dignity matters. We envision a world free of neurological disorders and that cutting-edge sciences and technologies are translated to the clinic to provide the best care for all the patients.
APRINOIA strives to bring cutting-edge sciences and technologies to life. We will continue to impel new standards in scientific research through our discoveries, innovations and technologies.
APRINOIA welcomes global and local partners to share our vision and values. We work with our partners with a great level of flexibility to create values and achieve our goals.
Our Teams
Ming-Kuei Jang
Founder and CEO
Paul Tempest
Senior Vice President of Drug Discovery
Chin-Yin Tai
Vice President of Neurobiology
Pei-Han Juan
Director of Finance
Masaomi Miyamoto
Executive Vice President of R&D and Operations (Tokyo)
PJ Chen
Senior Vice President of Clinical Development
Feng Yu
Vice President of Operations and Business Development (Suzhou)
Chien-Hui Hung
Director of Operations
Research & Development
/ Focus
Aprinoia discovers and develops first-in-class diagnostics and therapeutics for Alzheimer’s Disease (AD) and other tau-associated neurodegenerative diseases (Tauopathies). We achieve our mission by building comprehensive internal drug discovery and development capabilities and integrative collaborations with world-class scientists, research institutions and pharmaceutical companies to bring innovative ideas and scientific discoveries to life.
Aprinoia discovers and develops first-in-class diagnostics and therapeutics for Alzheimer’s Disease (AD) and other tau-associated neurodegenerative diseases (Tauopathies). We achieve our mission by building comprehensive internal drug discovery and development capabilities and integrative collaborations with world-class scientists, research institutions and pharmaceutical companies to bring innovative ideas and scientific discoveries to life.
Tao
Alzheimer’s Disease
Research & Development
Focus
APRINOIA discovers and develops first-in-class diagnostics and therapeutics for Alzheimer’s Disease (AD) and other tau-associated neurodegenerative diseases (Tauopathies). We achieve our mission by building comprehensive internal drug discovery and development capabilities and integrative collaborations with world-class scientists, research institutions and pharmaceutical companies to bring innovative ideas and scientific discoveries to life.
Aprinoia discovers and develops first-in-class diagnostics and therapeutics for Alzheimer’s Disease (AD) and other tau-associated neurodegenerative diseases (Tauopathies). We achieve our mission by building comprehensive internal drug discovery and development capabilities and integrative collaborations with world-class scientists, research institutions and pharmaceutical companies to bring innovative ideas and scientific discoveries to life.
Tau
Alzheimer’s Disease
Tauopathies
Tauopathies are neurodegenerative disorders caused by aggregation of Tau proteins with formations of neurofibrillary tangles.
Tau aggregates are not only found in AD, but also non-AD neurodegenerative diseases, including FTD, PSP, and CBS.
Synucleinopathies
Synucleinopathies are neurodegenerative disorders caused by abnormal aggregation of alpha-synuclein proteins with formations of insoluble fibrils.
Alpha-synuclein aggregates are found in major families of synucleinopathies, which include Parkinson Disease (PD), Dementia with Lewy Bodies (DLB), and Multiple System Atrophy (MSA).
Solutions
Diagnostics
APRINOIA is developing PET imaging tracers to detect the presence of NFT in the brain. Our technology will enable clinicians to monitor accurately the disease progression of Alzheimer’s and tauopathies and prompt early diagnosis and treatment of the diseases. In addition, our technology will enable the development of new therapeutics against the diseases by accurately assessing the efficacy of each development programme.
Therapeutics
APRINOIA has created a library of compounds that have shown therapeutic efficacy to Alzheimer’s and tauopathies.
Pipeline
Our Partners
News
December 28, 2021
APRINOIA Therapeutics Completed $40 Million Series C Financing in 2021
APRINOIA Therapeutics has completed Series C financing with a total amount of $40 million USD in 2021. The financing was led by Yantai Dongcheng Pharmaceutical Group and syndicated by current shareholders KTB Network, IMM, and TaiAn Technologies and several new investors, including Harvest Capital, a fund established by the Management Committee of Suzhou Industrial Park (SIP).
December 30, 2020
Insilico partners with APRINOIA on AI-powered neurodegenerative drug discovery
Insilico Medicine is pleased to announce that it has entered into a research collaboration with APRINOIA Therapeutics to utilize Insilico’s novel generative artificial intelligence (AI) technology to accelerate the discovery of next generation compounds targeting abnormal proteins in brain associated with neurodegenerative diseases.
December 16, 2020
APRINOIA Therapeutics Established Collaboration on Tau PET Imaging Tracer Development
APRINOIA Therapeutics Inc. today announced that they had executed a worldwide non-exclusive licensing agreement for Biogen Inc. (Nasdaq: BIIB) to access APRINOIA’s positron emission tomography (PET) imaging tracer, 18F-APN-1607, for neurodegenerative diseases. This is an extension of a collaboration between APRINOIA and Biogen to discover novel PET imaging tracers for visualization and quantification of abnormal tau protein accumulation in the brain.
October 28, 2020
APRINOIA Announces Approval from NMPA to Initiate Phase 3 Clinical Trial in China for 18F-APN-1607 Tau PET Imaging Tracer for Dementia
APRINOIA Therapeutics announced today that China National Medical Products Administration (NMPA) had approved to initiate Phase 3 clinical trial to evaluate APRINOIA’s positron emission tomography (PET) imaging tracer, 18F-APN-1607, targeting abnormal tau protein aggregates in brains of patients of cognitive impairment.
November 21, 2019
Initiation of a Phase 2 Multicenter Study of 18F-APN-1607, a Novel Diagnostic PET Imaging Tracer for the Characterization of Tau Burden in Alzheimer’s Disease
APRINOIA Therapeutics, Inc. announced today that it has initiated a Phase 2 multicenter, multinational study of 18F-APN-1607 in the US for its lead tau positron emission tomography (PET) tracer in Alzheimer's Disease (AD). The study (NCT number: NCT04141150) will compare tau deposition patterns in patients with mild cognitive impairment due to AD and dementia due to AD with patterns in healthy older adults.
August 30, 2019
APRINOIA Therapeutics has Initiated a Collaboration with Keio University in Tokyo, Japan
APRINOIA Therapeutics has initiated a collaboration with Keio University in Tokyo, Japan to profile patients with dementia using APRINOIA’s tau PET imaging tracer, 18F-APN-1607 (PM-PBB3). The collaboration is a part of the EKID (Eisai-Keio Innovation Laboratory for Dementia) study conducted by Keio University and Eisai Co. Ltd., which is supported by a research grant (No. JP17pc0101006) from AMED (Japan Agency for Medical Research and Development). APRINOIA is grateful for the opportunity to contribute to the study which might be useful for deeper understanding of dementia, especially Alzheimer’s Disease.
July 01, 2019
APRINOIA Therapeutics Selected and Joined JLABS @ Shanghai
APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that it has been selected to join Johnson & Johnson Innovation’s JLABS and is now a resident company of JLABS @ Shanghai.
For more information, please click on “More” for the original press release from Johnson & Johnson Innovation.
May 23, 2019
APRINOIA Therapeutics Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research
APRINOIA Therapeutics announces today that it has been awarded a research grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) for the development of alpha-synuclein PET imaging tracers.
March 26, 2019
2019 Taiwan Top 10 Coolest Tech Startups
APRINOIA was awarded as one of the top ten most innovative startups of Taiwan in 2019 by the Ministry of Science & Technology.
Careers
This information will be updated shortly.
Contact Us
台灣
Email ： contact@aprinoia.com
地址 ： 11503 臺北市南港區園區街3號17樓
辦公室電話： +886-2-2655-8868
Taiwan
Address ： 17F, No.3, Park St., Nangang District, Taipei City 11503
Phone ： +886-2-2655-8868
-------------------------------------------------------------------------------------------------------
中国大陆
邮箱 ： contact@aprinoia.com
地址 ： 苏州市工业园区星湖街218号 生物医药产业园B2号楼5楼503室 215123
办公室电话： +86-512-8777 8382
China
Address ： R503,5F,Building B2,218 Xing Hu Rd,Suzhou Industrial Park,Suzhou 215213
Phone ： +86-512-8777 8382
-------------------------------------------------------------------------------------------------------
日本
Email ： contact@aprinoia.com
所在地 ： 〒104ｰ0033 東京都中央区新川1-2-8 第5山京ビル5F
Tel ： +81-3-6280-4277
Japan
Address ： Shinkawa 1-2-8, Chuo-ku, Tokyo 104-0033, Japan
Phone ： +81-3-6280-4277